The clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation.
The platform can assist in matching the needs of a team of nationally and internationally authoritative experts to provide accurate diagnosis and treatment. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumour diseases have been significantly improved. Treatment needs to closely monitor efficacy and adverse reactions, adapting timely to changes in the disease.
Multidisciplinary collaboration (MDT) is particularly important for the integrated management of isolated malignant tumors. The platform serves a team of internationally authoritative experts in the field of blood tumours in China, providing the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.